Published online Sep 9, 2025. doi: 10.5492/wjccm.v14.i3.101327
Revised: February 3, 2025
Accepted: February 25, 2025
Published online: September 9, 2025
Processing time: 310 Days and 15.7 Hours
A major cause of mortality in the coronavirus disease 2019 (COVID-19) pandemic was acute respiratory distress syndrome (ARDS). Currently, moderate to severe ARDS induced by COVID-19 (COVID ARDS) and other viral and non-viral etiologies are treated by traditional ARDS protocols that recommend 12-16 hours of prone position ventilation (PPV) with neuromuscular blocking agents (NMBA) and a trial of inhaled vasodilators (IVd) if oxygenation does not improve. How
To evaluate the impact of PPV used alone or in combination with pulmonary IVd and/or NMBA in mechanically ventilated patients with moderate to severe ARDS during the COVID-19 pandemic.
A retrospective study at two tertiary academic medical centers compared out
Total 114 patients were included in this study. Baseline respiratory parameters and Sequential Organ Failure Assessment scores were significantly worse in the PPV group. ICU LOS and LOS were significantly longer for patients who were proned, but no mortality benefit or difference in VV-ECMO status was found. Among the subgroups, no difference in primary outcomes were found. In the secondary analysis, PPV was associated with a significant improvement in arterial oxygen partial pressure (PaO2)/fractional inspired oxygen (FiO2) (P/F) ratio from day 1 to day 4 (P < 0.05) and higher driving pressures day 5 to day 7 (P < 0.05). The combination of PPV and IVd together resulted in improvements in P/F ratio from day 1 to day 7 and plateau pressure on day 4 and day 6 (P < 0.05). PPV with NMBA was not associated with improvements in any of the secondary outcomes. The use of all three rescue therapies together resulted in improvements in lung compliance on day 2 (P < 0.05) but no other improvements.
In mechanically ventilated patients diagnosed with moderate to severe COVID ARDS, PPV and PPV with the addition of IVd produced a significant and sustained increase in P/F ratio. The combination of PPV, IVd and NMBA improved compliance however this did not reach significance. Mortality and LOS did not improve with adjunct therapies. Further research is warranted to determine the efficacy of these therapies alone and in combination in the treatment of COVID ARDS.
Core Tip: In this retrospective study at two tertiary academic medical centers during the initial coronavirus disease 2019 surge, we examine trends in ventilator mechanics and outcomes of 114 acute respiratory distress syndrome (ARDS) patients receiving three adjunct therapies (prone positioning, neuromuscular blockade and inhaled vasodilations). We found a significant improvement in arterial oxygen partial pressure/fractional inspired oxygen ratio with the addition of inhaled vasodilators while proning and in lung compliance with the addition of continuous neuromuscular blockade among others. Our groups were not large enough to detect a difference in mortality or length of stay. However, this study provides a large amount of data and multi-day trends to further our understanding of the physiologic response to multiple adjunct therapies for ARDS in combination.